Assisted Partner Notification to Augment HIV Treatment and Prevention in Kenya (APS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01616420|
Recruitment Status : Completed
First Posted : June 11, 2012
Last Update Posted : April 10, 2017
The main purpose of this implementation science study is to find out if providing aPS at 18 different Ministry of Health (MOH) VCT clinics in Kenya works and is cost-effective. This would enable co-investigators in the Kenyan MOH to justify funding to scale-up these services.
The primary aim of the study is to find out whether providing aPS to sexual partners of newly tested HIV-infected individuals can result in more sexual partners getting counseled and HIV tested and linked to HIV care programs for initiation of ART if appropriate. The investigators hypothesize that aPS will increase rates of case-finding, linkages to care, and ART initiation and will not result in social harm.
The second aim is whether aPS is cost-effective in the Kenyan setting. The investigators will estimate how much it costs (when compared to standard methods) to identify and link HIV-infected persons into care. The investigators will also determine how successful aPS is at preventing future HIV transmission events and other outcomes associated with untreated HIV infection. The investigators hypothesize that HIV prevalence among partners in the immediate aPS arm will be high enough to make this approach cost-effective from the payer and societal perspective.
Finally, with the Kenya MOH, the investigators want to establish a nationwide monitoring system to evaluate why Kenyans are testing for HIV. In the future, when aPS is rolled out nationally, this will help Kenyan public health officials define the contribution of aPS to HIV case-finding. The investigators hypothesize that the proportion of newly tested HIV-infected individuals who report testing because of known exposure to a person with HIV will represent a significant proportion of new cases and the investigators will be able to identify places in Kenya where aPS will have the greatest impact on HIV treatment and prevention.
|Condition or disease||Intervention/treatment|
|HIV||Other: Assisted-partner notification services|
Diagnosing HIV soon after infection can benefit individuals and also has important public health benefits. It has been shown that starting antiretroviral therapy (ART) before HIV has progressed results in a better response to treatment and gives the person a better chance of long-term survival with HIV. Treating HIV can also reduce the risk that someone will transmit HIV to his or her sexual partners. The first step in achieving these individual and population level benefits is testing people for HIV. Unfortunately, in many parts of the world, including Kenya where we plan to conduct this study, many people are not tested regularly and do not know that they are infected. This study involves providing a public health service, notification of an exposure to a communicable disease and HIV testing, to sexual partners of those who test HIV-positive at voluntary counseling and testing (VCT) clinics in Kenya. Sexual partners are identified voluntarily by the person who tests at the VCT. A public health provider then goes to the home of the sexual partners to offer them HIV counseling and testing. This process is called provision of assisted partner services (aPS).
We propose a cluster randomized clinical trial which will be conducted in collaboration with the Kenya Ministry of Health (MOH) at 18 rural and urban voluntary counseling and testing (VCT) facilities across Kenya. Proposed activities will assess the effectiveness and cost-effectiveness of providing aPS, improve capacity for program implementation in Kenya, and lay the foundation for evaluating the program's impact at the national level.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||2424 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Primary Purpose:||Health Services Research|
|Official Title:||Assisted Partner Notification to Augment HIV Treatment and Prevention in Kenya|
|Study Start Date :||June 2012|
|Primary Completion Date :||August 2015|
|Study Completion Date :||August 2015|
|No Intervention: Delayed aPS|
|Experimental: Immediate aPS||
Other: Assisted-partner notification services
Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
- Number of partners testing for HIV [ Time Frame: 6 week period following index case enrollment ]The number of partners of an index participant that were tested for HIV (offset will be the number of partners with locator information provided by the index participant).
- Newly tested HIV-infected partners [ Time Frame: 6 week period following index case enrollment ]The number of partners of an index participant identified as HIV-infected (offset will be the number of partners of that index participant who were HIV tested).
- Number of partners linking to HIV care [ Time Frame: 6 week period following index case enrollment ]The number of partners of an index participant who were linked to HIV care (offset will be the number of partners of an index participant identified as HIV-infected and analysis will be limited to index participants with at least one HIV-infected partner.)
- Incremental cost-effectiveness from payer and societal perspectives [ Time Frame: 6 week period following index case enrollment ]
- Proportion of individuals with newly diagnosed HIV infection who report testing because of known exposure to a person with HIV [ Time Frame: 6 week period after index case enrollment ]
- Costs of identifying >1 partner per index case [ Time Frame: 6 week period after index case enrollment ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01616420
|Kiambu Hospital VCT|
|Chulaimbo Health Centre|
|Joo Trh Vct|
|Kisumu East District Hospital|
|Baba Dogo VCT|
|Kenyatta National Hospital (KNH) VCT|
|Mama Lucy Kibaki VCT|
|Abidha Health Centre|
|Ongielo Health Centre|
|Principal Investigator:||Carey Farquhar, MD, MPH||University of Washington|
|Study Chair:||Peter Cherutich, MBChB, MPH||Kenya Ministry of Health|
|Study Chair:||Matthew Golden, MD, MPH||University of Washington|